中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
13期
9-11
,共3页
急性冠脉综合征%小檗碱%超敏 C-反应蛋白%心型脂肪酸结合蛋白%N 末端脑钠肽前体
急性冠脈綜閤徵%小檗堿%超敏 C-反應蛋白%心型脂肪痠結閤蛋白%N 末耑腦鈉肽前體
급성관맥종합정%소벽감%초민 C-반응단백%심형지방산결합단백%N 말단뇌납태전체
Acute coronary syndrome%Berberine%High-sensitivity C-reactive protein%Heart-type fatty acid binding protein%N-terminal pro-brain natriuretic peptide
目的：探讨小檗碱联合单倍剂量瑞舒伐他汀对急性冠脉综合征患者血超敏 C-反应蛋白（hs-CRP）、心型脂肪酸结合蛋白（H-FABP）和 N 末端脑钠肽前体（NT-proBNP）的影响。方法将96例急性冠脉综合征患者随机分为对照组和观察组，每组48例，对照组采用常规治疗加用瑞舒伐他汀20 mg，1次/晚；观察组采用常规治疗加用瑞舒伐他汀10 mg，1次/晚，小檗碱0.3 g，3次/ d。两组共治疗8周。治疗前后测定三酰甘油（TG）、胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、hs-CRP、H-FABP 和 NT-proBNP。结果两组患者治疗后血 TG、TC、LDL-C均有明显降低，但两组治疗后比较差异无统计学意义（P >0.05）。两组治疗后血 hs-CRP、H-FABP 和 NT-proBNP均有明显降低，并且观察组比对照组降低更明显（P <0.05）。对照组不良反应发生率为6.25%，观察组未出现不良反应，两组比较差异有统计学意义（P <0.05）。结论小檗碱联合单倍剂量瑞舒伐他汀可以明显降低急性冠脉综合征患者血 hs-CRP、H-FABP 和 NT-proBNP。
目的：探討小檗堿聯閤單倍劑量瑞舒伐他汀對急性冠脈綜閤徵患者血超敏 C-反應蛋白（hs-CRP）、心型脂肪痠結閤蛋白（H-FABP）和 N 末耑腦鈉肽前體（NT-proBNP）的影響。方法將96例急性冠脈綜閤徵患者隨機分為對照組和觀察組，每組48例，對照組採用常規治療加用瑞舒伐他汀20 mg，1次/晚；觀察組採用常規治療加用瑞舒伐他汀10 mg，1次/晚，小檗堿0.3 g，3次/ d。兩組共治療8週。治療前後測定三酰甘油（TG）、膽固醇（TC）、低密度脂蛋白膽固醇（LDL-C）、hs-CRP、H-FABP 和 NT-proBNP。結果兩組患者治療後血 TG、TC、LDL-C均有明顯降低，但兩組治療後比較差異無統計學意義（P >0.05）。兩組治療後血 hs-CRP、H-FABP 和 NT-proBNP均有明顯降低，併且觀察組比對照組降低更明顯（P <0.05）。對照組不良反應髮生率為6.25%，觀察組未齣現不良反應，兩組比較差異有統計學意義（P <0.05）。結論小檗堿聯閤單倍劑量瑞舒伐他汀可以明顯降低急性冠脈綜閤徵患者血 hs-CRP、H-FABP 和 NT-proBNP。
목적：탐토소벽감연합단배제량서서벌타정대급성관맥종합정환자혈초민 C-반응단백（hs-CRP）、심형지방산결합단백（H-FABP）화 N 말단뇌납태전체（NT-proBNP）적영향。방법장96례급성관맥종합정환자수궤분위대조조화관찰조，매조48례，대조조채용상규치료가용서서벌타정20 mg，1차/만；관찰조채용상규치료가용서서벌타정10 mg，1차/만，소벽감0.3 g，3차/ d。량조공치료8주。치료전후측정삼선감유（TG）、담고순（TC）、저밀도지단백담고순（LDL-C）、hs-CRP、H-FABP 화 NT-proBNP。결과량조환자치료후혈 TG、TC、LDL-C균유명현강저，단량조치료후비교차이무통계학의의（P >0.05）。량조치료후혈 hs-CRP、H-FABP 화 NT-proBNP균유명현강저，병차관찰조비대조조강저경명현（P <0.05）。대조조불량반응발생솔위6.25%，관찰조미출현불량반응，량조비교차이유통계학의의（P <0.05）。결론소벽감연합단배제량서서벌타정가이명현강저급성관맥종합정환자혈 hs-CRP、H-FABP 화 NT-proBNP。
Objective To study the effects of berberine combined with rosuvastatin on blood high-sensitivity C-reactive protein( hs-CRP),heart-type fatty acid binding protein( H-FABP)and N-terminal pro-brain natriuretic peptide( NT-proBNP)in patients with acute coronary syndrome. Meth-ods Ninety-six patients with acute coronary syndrome were randomly divided into two groups,the con-trol group(48 cases)and the observation group(48 cases). Patients in the control group were treated with the conventional treatment plus rosuvastatin 20 mg,1 time / night,while patients in the observation group were treated with the conventional method plus rosuvastatin 10 mg,1 time / night,berberine 0. 3 g,3 times / day. They were all treated for 8 weeks. The levels of triglyceride( TG),cholesterol (TC),low density lipoprotein(LDL-C),hs-CRP,H-FABP and NT-proBNP were detected before and af-ter treatment. Results After treatment,the serum TG,TC,LDL-C levels were significantly reduced, but there was no significant difference between the two groups after treatment(P > 0. 05). After treat-ment,the levels of serum hs-CRP,H-FABP and NT-proBNP significantly reduced,and those in the ob-servation group decreased more significantly than those in the control group(P < 0. 05). The incidence of adverse reactions was 6. 25% in control group,and there was no adverse reactionl in the observation group,there was significant difference between the two groups( P < 0. 05). Conclusions Berberine combined with rosuvastatin can decrease the blood levels of hs-CRP,H-FABP and NT-proBNP in patients with acute coronary syndrome.
